Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-612 in advanced solid tumors
NCT07032298Phase 1Recruiting
- Sponsor
- 3SBio
- Start
- Jul 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SSGJ-612 in solid tumor (advanced stage), sponsored by 3SBio. Primary endpoints: Incidence and severity of Adverse Events at 1 year and Incidence of Dose-Limiting Toxicity at 14 days. Started Jul 2025; status: recruiting.
02
Drugs
SSGJ-612
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07032298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07032298.